$330 Million is the total value of CHI Advisors LLC's 26 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ACELYRIN INC | $55,673,548 | – | 2,663,806 | +100.0% | 16.89% | – | |
| New | DISC MEDICINE INC | $5,556,172 | – | 125,139 | +100.0% | 1.69% | – | |
| LABD | New | DIREXION SHS ETF TRdaily s&p biotec | $4,670,250 | – | 325,000 | +100.0% | 1.42% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $3,921,050 | – | 85,000 | +100.0% | 1.19% | – |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $3,787,500 | – | 750,000 | +100.0% | 1.15% | – |
| HOOK | New | HOOKIPA PHARMA INC | $694,091 | – | 788,740 | +100.0% | 0.21% | – |
| GRPH | New | GRAPHITE BIO INC | $600,439 | – | 230,938 | +100.0% | 0.18% | – |
| PLRX | New | PLIANT THERAPEUTICS INCcall | $161,828 | – | 130,300 | +100.0% | 0.05% | – |
| New | FREELINE THERAPEUTICS HLDGSsponsored ads | $55,898 | – | 21,666 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-08-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.